CLINICAL INFECTIOUS DISEASES Journal

Overview
Identity
Ver todos

publication venue for

A Phase III Randomized Controlled Trial of Plitidepsin, a Marine-Derived Compound, in Hospitalized Adults With Moderate COVID-19. 910-919. 2024
Early Detection of Cancer and Precancerous Lesions in Persons with HIV through a Comprehensive Cancer Screening Protocol 2024
Virological History Predicts Non-sustained Viral Suppression with Long-Acting Cabotegravir and Rilpivirine Therapy, independent of Pharmacokinetic Parameters. 20-40. 2024
Human Immunodeficiency Virus Type 1 RNA Levels in Rectal and Seminal Compartments After Switching to Long-Acting Cabotegravir Plus Rilpivirine: A Longitudinal Study. 2023
Incidence of hypertension and blood pressure changes in persons with HIV athigh risk for cardiovascular disease switching from boosted protease inhibitors todolutegravir: a post-hoc analysis of the 96-week randomised NEAT-022 trial 2023
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial. 861-870. 2023
Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial. 116-125. 2023
Clinical Performance of a Standardized Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Interferon-¿ Release Assay for Simple Detection of T-Cell Responses After Infection or Vaccination. 338-346. 2022
Efficacy and Safety of Switching to Dolutegravir/Lamivudine (DTG/3TC) Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With HIV-1: Results Through Week 144 From the Phase 3, Non-inferiority TANGO Randomized Trial. 1-20. 2022
Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral Therapy.. 1324-1333. 2022
Human Immunodeficiency Virus Type 1 RNA Levels in Rectal and Seminal Compartments After Switching to Long-Acting Cabotegravir Plus Rilpivirine: A Longitudinal Study 2022
Severe Acute Respiratory Syndrome Coronavirus 2 Adaptive Immunity in Nursing Home Residents Following a Third Dose of the Comirnaty Coronavirus Disease 2019 Vaccine. 865-868. 2022
Clinical performance of a standardized SARS-CoV-2 interferon-¿ release assay for simple detection of T-cell responses after infection or vaccination. 1021-1025. 2021
Infection With Chlamydia trachomatis Increases the Risk of High-grade Anal Intraepithelial Neoplasia in People Living With Human Immunodeficiency Virus. 2161-2167. 2020
An Unusual Cause of Chronic Back Pain in a Migrant From Western Sahara.. 2131-2134. 2019
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ¿50 Years: Final 96-Week Results of the NEAT022 Study. 597-606. 2019
Immediate vs. Deferred Switching from a Boosted Protease Inhibitor (PI/r) Based Regimen to a Dolutegravir (DTG) Based Regimen in Virologically Suppressed Patients with High Cardiovascular Risk or Age ¿50 years: Final 96 Weeks Results of NEAT 022 study.. 1-7. 2018
Thymic Function Failure Is Associated With Human Immunodeficiency Virus Disease Progression. 1191-1197. 2017
Analysis of Non-AIDS-Defining Events in HIV Controllers. 1304-1309. 2016
Trasmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe. 655-664. 2016
Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries. 1262-1268. 2015
Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.. 1262-1268. 2015
Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe. 1-12. 2015
Differential Body Composition Effects of Protease Inhibitors Recommended for Initial Treatment of HIV Infection: A Randomized Clinical Trial. 1-10. 2014
Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery.. 1312-1321. 2014
Simeprevir (TMC435) With Pegylated Interferon/Ribavirin in Patients Coinfected With HCV Genotype 1 and HIV-1: A Phase 3 Study.. 1579-1587. 2014
Once-a-day highly active antiretroviral therapy: a systematic review. 1186-1190. 2013
Once-a-month administration of intravenous pentamidine to patients infected with human immunodeficiency virus as prophylaxis for Pneumocystis carinii pneumonia. 901-904. 2013
The incidence of AIDS-defining illnesses at a current CD4 count ¿ 200 cells/¿L in the post-combination antiretroviral therapy era. 1038-1047. 2013
Development of tropical spastic paraparesis in human T-lymphotropic virus type 1 carriers is influenced by interleukin 28B gene polymorphisms.. 1-4. 2012
Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. . 1364-1372. 2012
Decrease in serial prevalence of coinfection with hepatitis C virus among HIV-infected patients in Spain, 1997-2006. 1467-1470. 2009
Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).. 892-900. 2009
¿Asymptomatic bacteriuria in women with diabetes: influence of metabolic control?. . 1732-1733. 2008
Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. 1484-1492. 2007
Lack of efficacy of voriconazole therapy in patients with pulmonary fungus balls. . 1706-1707. 2005
Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy using therapeutic drug monitoring. . 1648-1653. 2005
Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis.. 670-676. 2005
Single-slice computed tomography scan and skinfold anthropometry to evaluate facial lipoatrophy in HIV-infected patients. 1848-1851. 2004
Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. 286-292. 2003
Evaluation of the immunochromatographic Binax Now assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. 286-292. 2003
Good interpretation of a diagnostic test (Reply). 1144-1145. 2003
A Janeway lesion and an Osler node. 63-149. 2001